Key facts
- Leon Nanodrugs’s last known valuation is $71.0M (Jul 2015).
- It has raised $20.5M; the latest was Later Stage VC in Feb 2026.
- Notable investors include LBBW Venture Capital, Albany Capital (Australia), Albany Private Equity Holding, Bayerische Beteiligungsgesellschaft, CB one Holding — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Leon Nanodrugs
- ·The full record, as it builds
Funding rounds
No funding rounds for Leon Nanodrugs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leon Nanodrugs
Developer of drugs through nanoscience designed to offer patient outcomes. The company's drugs specialize in improving the bioavailability of poorly water-soluble medicine by using their proprietary technology to create either polymeric or crystalline nanoparticles, enabling medical professionals to get nano-formulated drugs with meaningful differentiation and added benefits.
- Sector
- Healthcare
- HQ
- Planegg, Germany
- Founded
- 2010
- Employees
- 14
- Website
- leon-nanodrugs.com/
- Ownership
- Privately Held (backing)
Leon Nanodrugs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leon Nanodrugs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leon Nanodrugs in its N-PORT filings yet. We sweep new filings monthly.